Myriad Assures Investors of Strong Patent Position Despite ACLU Anti-Gene Patenting Lawsuit

According to CEO Peter Meldrum, Myriad’s strong IP position on the BRACAnalysis test and a large internal database of BRCA mutations ensure that "regardless of the outcome of this particular lawsuit, it will not have a material adverse effect on the company … or on the future revenues of our products."

Technology Developed by Liotta and Petricoin Used to Test Chloroquine to Treat Breast Cancer

The research will use reverse-phase protein microarray technology developed by Liotta and Petricoin to create a proteomic profile of tissue samples from trial participants in order to show which protein pathways or drug targets are activated, and then determine whether chloroquine has any effect as a treatment.

Abbott, GSK to Develop PCR-Based Molecular Dx to Select Patients for Trial Skin Cancer Therapy

Abbott and GSK will develop and commercialize a PCR test for the MAGE-A3 biomarker using Abbott's m2000 automated real-time PCR system.

Celera Turns Q4 Profit as Revenues Falter

Celera posted a profit, even though its Q4 revenues declined due to lower sales from its lab services business. The firm also guided for lower 2010 revenues than the market had previously expected due to issues surrounding that part of its business.

Abbott, GSK Pen Melanoma MDx Collaboration

Abbott will develop a molecular PCR-based test aimed at identifying patients who may benefit from a GSK drug for melanoma.

NHLBI Pledges up to $30M for Lung Centers

The CADET programs will support two-year projects for centers to develop diagnostics and therapeutics for lung diseases.

After GINA, Where Do Life Insurance Firms Stand on Using Genomic Information for Coverage Decisions?

A Maryland-based interest group for life insurers is lobbying the state legislature not to pass laws restricting the use of genetic information — an effort that underscores the prevailing view of payors that genetic data is no different than other clinical factors in making underwriting decisions.

FDA Chief Commits to Completing Rx/Dx Codevelopment Guidance This Year, Improving Regulatory Science

At a luncheon hosted by the Personalized Medicine Coalition last week, FDA Commissioner Margaret Hamburg said the agency will release its drug/diagnostic codevelopment guidance this year, and discussed how personalized medicine can be advanced through a new NIH/FDA partnership.

Pfizer Taps Medco to Educate Physicians in Wake of Unremarkable Sales of PGx-Guided HIV Drug

Although the collaboration is aimed at increasing physician knowledge of genomic testing associated with all HIV drugs, it appears to have stemmed from lower-than-expected sales of Pfizer's CCR5-antagonist Selzentry.

Medco Research Institute to Spearhead PGx Projects; Warfarin Study Results to be Released in March

Pharmacy-benefits manager Medco this week outlined some activities planned for the Medco Research Institute, which is spearheading the company's pharmacogenomics research efforts. Additionally, during the company's 2009 earnings call, officials discussed the acquisition of DNA Direct and the forthcoming release of results from a study looking at PGx-guided warfarin dosing.

From Genome Technology

Congenital Cardiac Union

NHLBI has united leading hospitals with a six-year grant to study the genetic and epigenetic causes of congenital heart disease.

Genotypes for Disease

With more and more robust tools, researchers are now able to interrogate connections between genotypes and phenotypes with greater effectiveness than ever before. But with all this data, the real challenge is making a difference at the bedside.

Targeting Cancer Epigenetics

Jean-Pierre Issa discusses his recent work targeting epigenetic pathways to treat leukemia.